Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.57 |
| ▸ | PSD | A5PKW4 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554343 | 0.93 | CNR1 (0.48) | CNR1PSDKDM4ELMNAPOLB | |
| SCHEMBL3560568 | 0.79 | CNR1 (0.47) | CNR1PSDKDM4ELMNAPOLB | |
| SCHEMBL3552541 | 0.79 | CNR1 (0.47) | CNR1PSDKDM4ELMNAPOLB | |
| SCHEMBL5214789 | 0.75 | GCGR (0.46) | CNR1PSDLMNAHTTSMN1; SMN2 | |
| SCHEMBL3555150 | 0.73 | GCGR (0.58) | PSDKDM4ELMNASMN1; SMN2MAPK11 | |
| SCHEMBL3554706 | 0.72 | CNR1 (0.48) | CNR1KDM4ELMNAPOLBHPGD | |
| SCHEMBL13114639 | 0.72 | CNR1 (0.73) | CNR1PSDCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14540776 | 0.71 | CNR1 (0.47) | CNR1PSDCYP3A4KDM4ELMNA | |
| SCHEMBL3557459 | 0.71 | HPGD (0.41) | CNR1PSDKDM4ELMNAPOLB | |
| SCHEMBL4389578 | 0.68 | KCNQ3 (0.47) | CNR1PSDKDM4ELMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816357-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1697371-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1697371-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050171110-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-04 | — | — | US | disclosed |
| WO-2005063762-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171110-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | CNR1 1/4885PSD 3213/4885CYP3A4 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.